Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas-2

<p><b>Copyright information:</b></p><p>Taken from "Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas"</p><p>BMC Cancer 2006;6():46-46.</p><p>Published online 28 Feb 2006</p><p>PMCID:PMC1431553.</p><p>Copyright © 2006 Kountourakis et al; licensee BioMed Central Ltd.</p>ction in the adenomatous part of lesion (× 200

HER-3 strong membranous and weak to moderate cytoplasmic staining (× 200)

<p><b>Copyright information:</b></p><p>Taken from "Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas"</p><p>BMC Cancer 2006;6():46-46.</p><p>Published online 28 Feb 2006</p><p>PMCID:PMC1431553.</p><p>Copyright © 2006 Kountourakis et al; licensee BioMed Central Ltd.</p

Raw Data TRAIL.xlsx

Cp raw data from real time RT-PCR experiments are included in this excel file<br

Schematic representation of the distribution (%) of different KRAS mutations.

<p>Schematic representation of the distribution (%) of different KRAS mutations.</p

EGFR mutations distributed amongst different Adenocarcinoma groups.

<p>EGFR mutations distributed amongst different Adenocarcinoma groups.</p

Pie charts representing the frequencies (%) of alterations of the examined genes in this cohort.

<p>Percentage of alterations for all the samples of the cohort (All NSCLC) and between the different histological types adenocarcinoma (AdCa), squamous cell carcinomas (Squamous), and other types (NOS and Other).</p

KRAS mutations distributed amongst different Adenocarcinoma groups.

<p>KRAS mutations distributed amongst different Adenocarcinoma groups.</p

Histological Classification of 956 NSCLC samples

<p>A. Classification of Resection Samples B. Classification of Small Biopsies/cytology samples and C. Metastasis Samples according to IASLC/ATS/ERS 2011, WHO 2015.</p

Frequencies of alterations between different groups of adenocarcinomas (NL = Normal, MT = Mutant, AMPL = gene amplification).

<p>Frequencies of alterations between different groups of adenocarcinomas (NL = Normal, MT = Mutant, AMPL = gene amplification).</p

Clinicopathological and demographic characteristics of NSCLC patients.

<p>Clinicopathological and demographic characteristics of NSCLC patients.</p